Sarc
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
- Conditions
- Epithelioid Hemangioendothelioma (EHE)
- Interventions
- Drug: nab-Sirolimus
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Target Recruit Count
- 41
- Registration Number
- NCT07104331
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
- Conditions
- HLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS)
- Interventions
- Drug: Physician's Choice
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Target Recruit Count
- 47
- Registration Number
- NCT06942442
SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
- Conditions
- Gastrointestinal Stromal TumorsGIST
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-01-31
- Target Recruit Count
- 40
- Registration Number
- NCT06208748
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
- Conditions
- Advanced Dedifferentiated Liposarcoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 108
- Registration Number
- NCT04967521
- Locations
- 🇺🇸
University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
- Conditions
- Osteosarcoma in ChildrenOsteosarcoma RecurrentOsteosarcoma MetastaticOsteosarcoma
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-04-18
- Target Recruit Count
- 48
- Registration Number
- NCT04803877
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next